Shots:

• Beacon will take care of drug discovery activities while Arena will focus on development and commercialization of products for multiple immune and inflammatory diseases
• The focus of the agreement is to develop therapies for G protein-coupled receptor (GPCR) targets and further expanding the footprints in autoimmune diseases
• Arena has a pipeline of three candidates APD418- Olorinab- and Etrasimod. Etrasimod is a qd- PO- selective sphingosine 1-phosphate (S1P) receptor modulator targeted for multiple immune-mediated inflammatory diseases including UC- Crohn’s disease- and atopic dermatitis

Click here to read full press release/ article | Ref: Arena | Image: Twitter